Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients

NCT ID NCT02344680

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver cancer. The findings could help design future studies aimed at curing hepatitis B.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Anti-HIV Agents (antiretroviral therapy)

What this could lead to

If successful, this research could identify key risk factors for liver cancer and help design future studies for a hepatitis B cure.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not apply to other populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS alcoholic hepatitis cirrhosis of liver fibrotic liver disease hepatitis B virus infection hepatitis D virus infection hepatocellular carcinoma HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Centre for Infectious Disease Research in Zambia (CIDRZ)

    Lusaka, Lusaka Province, 34681, Zambia